Telitacicept for lupus: safety and effectiveness trial
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new biologic drug called telitacicept for people with systemic lupus erythematosus (SLE). It aims to see how safe and effective the drug is and may offer a new treatment option for lupus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with systemic lupus erythematosus (SLE) using the 2019 ACR/EULAR criteria.
- You are willing to take the study drug telitacicept.
- You do not have other rheumatic or autoimmune diseases.
- You do not have an active infection (like a serious cold or pneumonia).
- You are not currently using other biologic medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
This study compares two medications, Telitacicept and Belimumab, to see which works better for people with active lupus that hasn't improved with standard treatments. The goal is to find a more effective option for managing symptoms.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
This trial tests telitacicept to improve lupus nephritis (inflammation of the kidneys caused by lupus). It targets people with active kidney disease confirmed by biopsy and compares outcomes while you receive standard steroid plus mycophenolate treatment.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.